OTCMKTS:BSTG Biostage (BSTG) Stock Price, News & Analysis → I tried to warn you (From Porter & Company) (Ad) Free BSTG Stock Alerts $4.45 0.00 (0.00%) (As of 07/24/2023) Add Compare Share Share Today's Range$4.45▼$4.4550-Day Range$4.45▼$4.4552-Week Range$4.45▼$4.45VolumeN/AAverage Volume1,847 shsMarket Capitalization$61.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biostage alerts: Email Address Ad True Market InsidersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... Today, he is now making the biggest crypto call of his ENTIRE career…Click For My #1 FREE Crypto for 2024 About Biostage Stock (OTCMKTS:BSTG)Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.Read More BSTG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BSTG Stock News HeadlinesJanuary 5, 2024 | investing.comHarvard Apparatus Regenerative Technology Inc (HRGN)August 22, 2023 | seekingalpha.comHRGN Harvard Apparatus Regenerative Technology Inc.July 20, 2023 | finance.yahoo.comBiostage, Inc. Changes Name to Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN)July 18, 2023 | finance.yahoo.comBiostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal DiseaseJuly 11, 2023 | benzinga.comBiostage CEO Awarded $1.07M Worth of Stock OptionsJune 13, 2023 | finance.yahoo.comBiostage to Host Investor CallMay 31, 2023 | finance.yahoo.comBiostage Initiated Study Start-up Activities for Clinical Trial in Severe Esophageal DiseaseMay 16, 2023 | benzinga.comBiostage Stock (OTC:BSTG), Insider Trading ActivityApril 24, 2023 | sg.finance.yahoo.comBiostage, Inc. (BSTG) stock historical prices & data – Yahoo FinanceApril 23, 2023 | ca.finance.yahoo.comBiostage, Inc. (BSTG) Stock Historical Prices & Data - Yahoo FinanceApril 10, 2023 | finance.yahoo.comBiostage Appoints Ron Packard to Board of DirectorsApril 6, 2023 | finance.yahoo.comBiostage Announces $6 Million Financing to Advance Clinical TrialMarch 2, 2023 | finance.yahoo.comBiostage Announces Chairman and CEO TransitionFebruary 3, 2023 | msn.comRegenerative medicine developer Biostage cancels Nasdaq uplisting, public offeringJanuary 12, 2023 | finance.yahoo.comBiostage Amends CEO Employment AgreementDecember 28, 2022 | finance.yahoo.comBiostage, Inc. (OTC:BSTG) Q3 2022 Earnings Call TranscriptDecember 28, 2022 | prnewswire.comBiostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including CancerDecember 23, 2022 | finance.yahoo.comNew Publication Demonstrates Rapid Esophageal Regeneration using the Biostage Esophageal ImplantNovember 15, 2022 | seekingalpha.comBiostage, Inc. (BSTG) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | finance.yahoo.comBiostage Reports Corporate Highlights and Third Quarter Financial ResultsNovember 10, 2022 | finance.yahoo.comBiostage Schedules Conference Call and Webcast for Q3 2022 ResultsOctober 29, 2022 | seekingalpha.comRegenerative therapy developer Biostage files for Nasdaq uplisting, $6M offeringOctober 25, 2022 | finance.yahoo.comBiostage Receives U.S. Patent for Cellularized Patch-Based Scaffolds for Organ RepairAugust 8, 2022 | finance.yahoo.comBiostage Announces Appointment of New Chief Financial OfficerAugust 4, 2022 | finance.yahoo.comBiostage Reports Corporate Highlights and Second Quarter Financial ResultsSee More Headlines Receive BSTG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biostage and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2020Today6/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolOTCMKTS:BSTG CUSIPN/A CIK1563665 Webwww.biostage.com Phone(744) 233-7300Fax774-233-7302Employees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,070,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-174.43% Debt Debt-to-Equity RatioN/A Current Ratio2.73 Quick Ratio2.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.26) per share Price / Book-17.12Miscellaneous Outstanding Shares13,882,000Free Float11,758,000Market Cap$61.77 million OptionableNot Optionable Beta-1.02 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Junli He (Age 49)CEO & Chairman Mr. Yu Hong (Age 50)Pres Comp: $158.06kDr. William L. Fodor Ph.D. (Age 64)Chief Scientific Officer Comp: $207.85kMr. Joseph L. Damasio Jr. (Age 49)Chief Financial Officer Dr. Shunfu Hu Ph.D.VP of Bus. Devel. & OperationsKey CompetitorsUtah Medical ProductsNASDAQ:UTMDAVITA MedicalNASDAQ:RCELProfound MedicalNASDAQ:PROFCVRxNASDAQ:CVRXDelcath SystemsNASDAQ:DCTHView All Competitors BSTG Stock Analysis - Frequently Asked Questions How have BSTG shares performed in 2024? Biostage's stock was trading at $4.45 at the beginning of 2024. Since then, BSTG shares have increased by 0.0% and is now trading at $4.45. View the best growth stocks for 2024 here. How were Biostage's earnings last quarter? Biostage, Inc. (OTCMKTS:BSTG) released its quarterly earnings results on Thursday, August, 13th. The company reported ($0.14) EPS for the quarter. What other stocks do shareholders of Biostage own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biostage investors own include Fulcrum Therapeutics (FULC), Allena Pharmaceuticals (ALNA), VIVUS (VVUS), Aldeyra Therapeutics (ALDX), Arbutus Biopharma (ABUS), Akero Therapeutics (AKRO), Ampliphi Biosciences (APHB), Ardelyx (ARDX), Armata Pharmaceuticals (ARMP) and Athersys (ATHX). How do I buy shares of Biostage? Shares of BSTG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BSTG) was last updated on 6/12/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredI tried to warn you America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story o...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biostage, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biostage With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.